PRMT5 and hepatocellular carcinoma: In hepatocellular carcinoma, DW14800, a novel inhibitor of protein arginine methyltransferase 5 (PRMT5), promotes the differentiation of CSCs by downregulating the expression of HNF4α and enhancing methylation of H4R3me2s [188].